** Shares of Chinese immunology diseases therapeutics developer Hbm Holdings Ltd 2142.HK rise 4.8% to HK$6.27, their highest since January 2022, and on course for second session of gains

** Hbm says co, as a licensor in a license agreement for product HBM9378/SKB378, has received an upfront payment from licensee Windward Bio AG, which will bolster co's cash reserves

** It gives no further details

** Hong Kong's healthcare index .HSCIH climbs 1.1%, Hang Seng Index .HSI rises 2.5%

** Stock up 221.5% YTD

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))